Evidence map›Paper›PMID 26061604›Full record

ArticleInternational journal of cancer2015

Mangrove dolabrane-type of diterpenes tagalsins suppresses tumor growth via ROS-mediated apoptosis and ATM/ATR-Chk1/Chk2-regulated cell cycle arrest.

Jennifer Neumann, Yi Yang, Rebecca Köhler, Marco Giaisi, Mathias Witzens-Harig, Dong Liu, Peter H Krammer, Wenhan Lin, Min Li-Weber

Abstract read
In one paragraph

Article in International journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Heliyon · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Ataxia-Telangiectasia Mutated (ATM) Protein Signaling Participates in Development of Pulmonary Arterial Hypertension in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jennifer NeumannTumorimmunology Program (D030), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Yi YangState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, People's Republic of China.
Rebecca KöhlerTumorimmunology Program (D030), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marco GiaisiTumorimmunology Program (D030), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Mathias Witzens-HarigMedizinische Klinik V Hämatologie, Onkologie und Rheumatologie, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.
Dong LiuState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, People's Republic of China.
Peter H KrammerTumorimmunology Program (D030), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wenhan LinState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, People's Republic of China.
Min Li-WeberTumorimmunology Program (D030), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural compounds are an important source for drug development. With an increasing cancer rate worldwide there is an urgent quest for new anti-cancer drugs. In this study, we show that a group of dolabrane-type of diterpenes, collectively named tagalsins, isolated from the Chinese mangrove genus Ceriops has potent cytotoxicity on a panel of hematologic cancer cells. Investigation of the molecular mechanisms by which tagalsins kill malignant cells revealed that it induces a ROS-mediated damage of DNA. This event leads to apoptosis induction and blockage of cell cycle progression at S-G2 phase via activation of the ATM/ATR-Chk1/Chk2 check point pathway. We further show that tagalsins suppress growth of human T-cell leukemia xenografts in vivo. Tagalsins show only minor toxicity on healthy cells and are well tolerated by mice. Our study shows a therapeutic potential of tagalsins for the treatment of hematologic malignancies and a new source of anticancer drugs.

Indexed as

AnimalsAntineoplastic AgentsApoptosisAtaxia Telangiectasia Mutated ProteinsCell Cycle CheckpointsCell Line, TumorCheckpoint Kinase 1Checkpoint Kinase 2DiterpenesDNA DamageG2 PhaseHumansJurkat CellsLeukemia, T-CellMiceProtein KinasesAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsATM protein, humanATR protein, humanCheckpoint Kinase 1Checkpoint Kinase 2CHEK1 protein, humanChek1 protein, mouseCHEK2 protein, humanDiterpenesProtein KinasesReactive Oxygen SpeciesTumor Suppressor ProteinsapoptosisATMATRcancerCdc25AChk1Chk2

Identifiers

PMID26061604
PMCPMC4755134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.